vutrisiran
Selected indexed studies
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. (N Engl J Med, 2025) [PMID:39213194]
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. (Amyloid, 2023) [PMID:35875890]
- Vutrisiran. (, 2006) [PMID:40587651]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. (2025) pubmed
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. (2023) pubmed
- Vutrisiran. (2006) pubmed
- Vutrisiran. (2012) pubmed
- Vutrisiran Improves Survival and Reduces Cardiovascular Events in ATTR Amyloid Cardiomyopathy: HELIOS-B. (2025) pubmed
- Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy. (2024) pubmed
- Vutrisiran: A Review in Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis. (2023) pubmed
- PMID:40080616 (2023) pubmed
- Single-Dose Pharmacokinetics and Pharmacodynamics of Transthyretin Targeting N-acetylgalactosamine-Small Interfering Ribonucleic Acid Conjugate, Vutrisiran, in Healthy Subjects. (2021) pubmed
- Impact of Vutrisiran on Functional Capacity and Quality of Life in Transthyretin Amyloidosis With Cardiomyopathy. (2025) pubmed